Getting Gene Therapies to Patients
This blog discusses the challenges that drug developers face in getting patients access to cell and gene therapies as well as some potential solutions.
Author: Ulrich Neumann
ICER’s Unsupported Drug Price Increase Report: An Analysis
We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported Price Increases.”
Real World Evidence Marches Forward in Drug Development
The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm on real-world evidence (RWE) and its adoption in the drug development process. While the collection of real-world data (RWD) and use of RWE is not new, they are now poised to have a profound impact on our industry. Today, it … Continued
1 of 1
